Primary CNS Lymphoma Clinical Trials 
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.Relapsed or Refractory Primary Diffuse Large B-cell Lymphoma (DLBCL) of the Central Nervous System (CNS)
Condition: DLBCL Interventions: Drug: Tislelizumab; Drug: Pemetrexed Sponsors: Seoul National University Hospital; Seoul National University Bundang Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 23, 2022 Category: Research Source Type: clinical trials
Phase 1 Study of Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid With Nivolumab (VIPOR-Nivo) for Diffuse Large B-cell Lymphoma Involving the Central Nervous System
Conditions: Primary Diffuse Large B-cell Lymphoma of the Central Nervous System (CNS); Aggressive B-cell Lymphoma With Secondary Involvement of the CNS Interventions: Drug: Obinutuzumab; Drug: Nivolumab; Drug: Prednisone; Drug: Lenalidomide; Drug: Venetoclax; Drug: Ibrutinib Sponsor: National Cancer Institute (NCI) Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 27, 2022 Category: Research Source Type: clinical trials
